Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Check out the Quiver Quantitative site for updates on what's going on behind the scenes in DC. Follow Quiver️ • TikTok - • ...

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...

Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 weight ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

The directive for the Department of Health and Human Services to develop and test new models aimed at lowering drug costs ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Will Medicare end Novo Nordisk's obesity drug boom? It's not surprising that CMS chose Ozempic, Wegovy, and Rybelsus for Medicare drug price negotiations. Between November 2023 and October 2024 ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...